Evidence map›Paper›PMID 41279184›Full record

ArticlebioRxiv : the preprint server for biology2025

Design of Tissue-Selective PROTACs Through Recruiting E3 Ligase Scaffolding Protein MAGEA11.

Isabella E Jacobsen, Rui Shi, Cole R Scholtz, William C K Pomerantz, Gunda I Georg

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Isabella E JacobsenDepartment of Chemistry, College of Science and Engineering, University of Minnesota, 207 Pleasant St SE, Minneapolis, MN 55455, USA.ORCID 0000-0003-0688-7119
Rui ShiDepartment of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, 717 Delaware Street SE, Minneapolis, MN 55414, USA.
Cole R ScholtzDepartment of Chemistry, College of Science and Engineering, University of Minnesota, 207 Pleasant St SE, Minneapolis, MN 55455, USA.ORCID 0000-0002-3654-5075
William C K PomerantzDepartment of Chemistry, College of Science and Engineering, University of Minnesota, 207 Pleasant St SE, Minneapolis, MN 55455, USA.
Gunda I GeorgDepartment of Chemistry, College of Science and Engineering, University of Minnesota, 207 Pleasant St SE, Minneapolis, MN 55455, USA.ORCID 0000-0002-8900-9460

Funding

TRAINING FOR FUTURE BIOTECHNOLOGY DEVELOPMENTT32GM008347 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI SCHMIDT-DANNERT, CLAUDIA · 1990 to 2021
$11.0M
Training the Next Generation of Chemical BiologistsT32GM132029 · NIGMS · UNIVERSITY OF MINNESOTA · PI Erin Elizabeth Carlson, William Charles Krause Pomerantz · 2019 to 2026
$2.7M
Chemical Probe Development for Epigenetic Complexes Enabled by Protein-Observed 19F NMRR35GM140837 · NIGMS · UNIVERSITY OF MINNESOTA · PI William Charles Krause Pomerantz · 2021 to 2026
$2.5M
NIGMS NIH HHS R35 GM140837NIGMS NIH HHS T32 GM008347NIGMS NIH HHS T32 GM132029
6 · The paper itself

Abstract

Proteolysis targeting chimeras (PROTACs) are an emerging therapeutic modality that induces protein degradation by recruiting E3 ligases. Most reported PROTACs recruit ubiquitously expressed E3 ligases, such as cereblon and the von Hippel-Lindau tumor suppressor. Of the additional 600+ E3 ligases, recruiting those with tissue-restricted expression is attractive for increasing the specificity of PROTACs. To this end, tissue-specific E3 ligases or E3 ligase-associated proteins that can be recruited for targeted protein degradation need to be identified. This work describes the first reported PROTAC that recruits the tissue-specific E3 ligase scaffolding protein MAGEA11. As an initial demonstration, a library of bromodomain and extra-terminal domain (BET)-targeting PROTACs that recruit MAGEA11 was synthesized. The library was screened in osteosarcoma U2OS cells, identifying lead compound 105B. 105B potently degrades BET proteins in U2OS osteosarcoma cell lines (BRD4 DC

Identifiers

PMID41279184
PMCPMC12637679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.